{Reference Type}: Journal Article
{Title}: Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report.
{Author}: Tamellini E;Simio C;Bernardelli A;Ferrarini I;Vatteroni A;Moioli A;Macaluso V;Marchetti E;Tanasi I;
{Journal}: Ann Hematol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 3
{Factor}: 4.03
{DOI}: 10.1007/s00277-024-05922-6
{Abstract}: Combined therapy with venetoclax and hypomethylating agents has significantly improved the outcome of unfit patients ineligible for intensive chemotherapy. A recently published exploratory analysis of the VIALE-A trial reported that up to 51% of patients achieving remission survived more than 2 years. These data along with those from reallife settings, lead to questioning how long it is appropriate to continue treatment in long-term survivors. Accordingly, recent retrospective studies suggested the feasibility of suspending therapy in selected patients while maintaining prolonged responses. Also, these studies showed that retreatment may induce a second remission in almost a third of patients. We report the case of a patient who received salvage therapy with venetoclax and azacytidine, that was discontinued few cycles after blasts clearance because of severe hematological toxicity. Despite suspension, he maintained a sustained response lasting almost one year and was successfully retreated with the same combination when a second relapse occurred.